{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T00:36:08Z","timestamp":1760834168745,"version":"build-2065373602"},"reference-count":30,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T00:00:00Z","timestamp":1668470400000},"content-version":"unspecified","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2022,10,19]]},"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Neratinib plus capecitabine (Ner+Cap) were proved to be clinically beneficial as a third-line treatment for women with human epidermal growth factor receptor-2 (HER2) positive metastatic breast cancer (MBC). The objective of this study was to evaluate the cost-effectiveness of Ner+Cap from the Chinese healthcare perspective.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>A three-state Markov simulation model was performed based on the results of NALA trial. The utilities of health state and disutilities of adverse events were derived from the published literature. Direct costs of anticancer agents, drug administration, routine follow-up and serious adverse events management were calculated in the model. Uncertainty was evaluated through univariate and probability sensitivity analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Participants<\/jats:title>\n                  <jats:p>Patients with confirmed HER2-positive MBC who previously received at least two HER2-targeted treatments and were aged \u226518 years with an Eastern Cooperative Oncology Group performance status 0 or 1. A total of 621 patients were enrolled in the NALA trial.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Interventions<\/jats:title>\n                  <jats:p>Third-line treatment with Ner+Cap\u2009or lapatinib plus capecitabine (Lap+Cap).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main outcome measures<\/jats:title>\n                  <jats:p>The primary health outcomes of the model were costs, expected life-years (LYs), quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios (ICERs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>When compared with Lap+Cap, Ner+Cap provided an additional 0.431 LYs and 0.339 QALYs, and increased the cost by $4299.2. The corresponding ICERs were 9970.1\/LY and $12 670.2\/QALY. Univariate sensitivity analyses suggested that the results were generally robust. Besides, Ner+Cap had a 100% probability of being cost-effective according to probabilistic sensitivity analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Ner+Cap was likely to be a cost-effective regimen as the third-line therapy for women with HER2-positive MBC at the willingness-to-pay threshold of $37 653.0\/QALY in China.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjopen-2022-065299","type":"journal-article","created":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T11:40:29Z","timestamp":1668512429000},"page":"e065299","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Neratinib plus capecitabine versus lapatinib plus capecitabine as the third-line therapy for HER2-positive metastatic breast cancer in China: a cost-effectiveness analysis"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4276-6640","authenticated-orcid":false,"given":"Yue","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Logistics Management, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhu","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hangzhou Linping District Traditional Chinese Hospital, Hangzhou, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiangfeng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Ipharmacare Ltd, Hangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingxia","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Zhejiang Provincial People's Hospital\uff08Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,11,15]]},"reference":[{"key":"2025101810260786000_12.11.e065299.1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer J Clin"},{"key":"2025101810260786000_12.11.e065299.2","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-3766.2019.01.005"},{"key":"2025101810260786000_12.11.e065299.3","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-74039-3_1"},{"key":"2025101810260786000_12.11.e065299.4","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4652(200002)182:2<150::AID-JCP3>3.0.CO;2-E"},{"key":"2025101810260786000_12.11.e065299.5","first-page":"798","article-title":"[Expert consensus on the management of adverse events of ErbB family tyrosine kinase inhibitors in breast cancer]","volume":"42","author":"Wang","year":"2020","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"2025101810260786000_12.11.e065299.6","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1201222"},{"key":"2025101810260786000_12.11.e065299.7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102033","article-title":"Her2-Positive advanced breast cancer treatment in 2020","volume":"88","author":"Cesca","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"2025101810260786000_12.11.e065299.8","unstructured":"Chinese Society of Clinical Oncology Guidelines Committee . Guidelines of Chinese Society of clinical oncology (CSCO) for breast cancer diagnosis and treatment 2021. Peking: People\u2019s Medical Publishing House, 2021."},{"key":"2025101810260786000_12.11.e065299.9","first-page":"2103","article-title":"Mechanism, safety and efficacy of three tyrosine kinase inhibitors lapatinib, neratinib and pyrotinib in HER2-positive breast cancer","volume":"9","author":"Xuhong","year":"2019","journal-title":"Am J Cancer Res"},{"key":"2025101810260786000_12.11.e065299.10","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1200\/JCO.20.00147","article-title":"Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with \u2265 2 HER2-Directed regimens: phase III NALA trial","volume":"38","author":"Saura","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025101810260786000_12.11.e065299.11","unstructured":"National Comprehensive Cancer Network (NCCN) . NCCN clinical practice guidelines in oncology. Breast cancer, version, 2022. Available: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1419"},{"key":"2025101810260786000_12.11.e065299.12","unstructured":"Food and Drug Administration . FDA approves neratinib for metastatic HER2-positive breast cancer. Available: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-neratinib-metastatic-her2-positive-breast-cancer [Accessed 20 Feb 2022]."},{"key":"2025101810260786000_12.11.e065299.13","doi-asserted-by":"crossref","first-page":"253","DOI":"10.21147\/j.issn.1000-9604.2017.03.11","article-title":"Expenditure of hospital care on cancer in China, from 2011 to 2015","volume":"29","author":"Cai","year":"2017","journal-title":"Chin J Cancer Res"},{"key":"2025101810260786000_12.11.e065299.14","doi-asserted-by":"crossref","first-page":"419","DOI":"10.21147\/j.issn.1000-9604.2017.05.06","article-title":"Analysis of inpatient payments of breast cancer patients with different medical insurance coverages in China (mainland) in 2011-2015","volume":"29","author":"Li","year":"2017","journal-title":"Chin J Cancer Res"},{"key":"2025101810260786000_12.11.e065299.15","unstructured":"National Bureau of Statistics of China . The growth rate of the total population slows down and the level of urbanization continues to rise. Available: http:\/\/www.stats.gov.cn\/tjsj\/zxfb\/202001\/t20200119_1723767.html [Accessed 27 Mar 2021]."},{"key":"2025101810260786000_12.11.e065299.16","unstructured":"Liu GN , SL H , JH W . [China Guidelines for Pharmacoeconomic Evaluations(2011)]. China Journal of Pharmaceutical Economics 2011:6-9+11\u201348."},{"key":"2025101810260786000_12.11.e065299.17","doi-asserted-by":"crossref","unstructured":"National Bureau of Statistics of China . China statistical yearbook, 2020. Available: http:\/\/www.stats.gov.cn\/tjsj\/ndsj\/2020\/indexch.htm [Accessed 28 Nov 2021].","DOI":"10.70190\/jq.I84.p154"},{"key":"2025101810260786000_12.11.e065299.18","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X15622643"},{"key":"2025101810260786000_12.11.e065299.19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151846","article-title":"Trial-Based cost-utility analysis of Icotinib versus gefitinib as second-line therapy for advanced non-small cell lung cancer in China","volume":"11","author":"Zhang","year":"2016","journal-title":"PLoS One"},{"key":"2025101810260786000_12.11.e065299.20","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0440-9"},{"key":"2025101810260786000_12.11.e065299.21","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1007\/s12325-020-01418-7","article-title":"Economic evaluation of cisplatin plus gemcitabine versus paclitaxel plus gemcitabine for the treatment of first-line advanced metastatic triple-negative breast cancer in China: using Markov model and partitioned survival model","volume":"37","author":"Rui","year":"2020","journal-title":"Adv Ther"},{"key":"2025101810260786000_12.11.e065299.22","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1080\/13696998.2019.1588125","article-title":"Cost-Effectiveness analysis of utidelone plus capecitabine for metastatic breast cancer in China","volume":"22","author":"Liao","year":"2019","journal-title":"J Med Econ"},{"key":"2025101810260786000_12.11.e065299.23","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603326"},{"key":"2025101810260786000_12.11.e065299.24","unstructured":"National Institute for Health and Care Excellence . Guide to the methods of technology appraisal, 2013. Available: https:\/\/www.nice.org.uk\/article\/pmg9\/resources\/non-guidance-guide-to-the-methods-of-technology-appraisal-2013-pdf [Accessed 11 Feb 2022]."},{"key":"2025101810260786000_12.11.e065299.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1405158"},{"key":"2025101810260786000_12.11.e065299.26","unstructured":"National Bureau of Statistics of China . Statistical communique of the people\u2019s republic of china on the 2021 national economic and social development. Available: http:\/\/www.stats.gov.cn\/xxgk\/sjfb\/zxfb2020\/202202\/t20220228_1827971.html [Accessed 1 Mar 2022]."},{"key":"2025101810260786000_12.11.e065299.27","first-page":"1133","article-title":"Cost-Effectiveness analysis of adjuvant neratinib following trastuzumab in early-stage HER2-positive breast cancer","volume":"25","author":"Schwartz","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"key":"2025101810260786000_12.11.e065299.28","unstructured":"Canadian Agency for Drugs and Technologies in Health . pan-Canadian oncology drug review final economic guidance report neratinib (Nerlynx) for early breast cancer. Available: https:\/\/cadth.ca\/sites\/default\/files\/pcodr\/Reviews2019\/10172NeratinibEBC_inEGR_NOREDACT-ABBREV_Post_05Dec2019_final.pdf [Accessed 20 Jun 2021]."},{"key":"2025101810260786000_12.11.e065299.29","unstructured":"National Medical Security Administration . National medical insurance drug list, 2021. Available: http:\/\/www.nhsa.gov.cn\/art\/2021\/12\/3\/art_37_7429.html [Accessed 03 Jan 2022]."},{"key":"2025101810260786000_12.11.e065299.30","unstructured":"Yaozhi Data Service Provider . Drug information inquiry. Available: https:\/\/db.yaozh.com\/yaopinzhongbiao [Accessed 5 Jan 2022]."}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-065299","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T17:26:22Z","timestamp":1760808382000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-065299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":30,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11,15]]},"published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1136\/bmjopen-2022-065299"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-065299","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2022,11]]}}}